The Catalyst

Most Recent Posts

02.08.12 | By Preet Bilinski

The PhRMA Foundation recently announced its 2012 award recipients and one, Lindsay Garvin, is right in our backyard from the George Washington University's School of Medicine and Health Sciences. She is a doctoral candidate pursuing a Ph.D.

02.07.12 | By Jennifer Wall

The White House today unveiled new efforts to help fight Alzheimer' disease, including providing additional funding for research, caregiver support and provider education.

02.07.12 | By Kate Connors

In the coming weeks and months, we're hoping to have some contributions to The Catalyst by PhRMA President and CEO John Castellani. Some of them may be quick interviews with me, and some may be thoughts that he wants to put down on paper.

To that end, I'd like to hear what our Catalyst readers would like to hear John discuss. Leave your comments below or Tweet me @KateAtPhRMA.

02.02.12

There's a potentially very exciting story in today's New York Times that's worth a look. Researchers doing mouse studies have apparently learned some important new information about how Alzheimer's disease spreads in the brain.

02.01.12 | By Preet Bilinski

If not, don't worry: you are not alone. However, considering that more than 13 million Americans suffer from the disease and an additional 12 million likely have it without knowing it, it's time to learn.

02.01.12 | By Jennifer Wall

I was just getting my daily dose of pharma news from Pharmalot and ran across an interesting blog post about prescribing decisions made by doctors. Ed Silverman, the man behind Pharmalot, highlighted a recent study that examined how a group of physicians view the prescribing of generic drugs.

02.01.12

I want to recommend an interesting piece in Salon. Author Mary Elizabeth Williams writes about her participation in a Phase I immunotherapy clinical trial for a Stage 4 melanoma. It is an eyes-open and moving account of her condition, hopes and fears as she recounts her participation in the trial and the first, preliminary results.

01.30.12

Impressive efforts are increasingly underway to bring together biopharmaceutical research companies, world governments and key non-governmental organizations (NGOs) in the global fight against often neglected tropical diseases (NTDs).

01.30.12 | By Kate Connors

Earlier this month, I wrote about the news that India has gone a full year without a new polio diagnosis - a big step forward to eradicating the disease.

01.30.12 | By Kate Connors

Today, PhRMA announced that we are transferring the future development of our benefit-risk assessment framework to the Centre for Innovation in Regulatory Science. As our press release stresses, this move is intended to further the framework - which we developed over the course of six years from an analytical model to a functional pilot program - so that the principles can be more broadly available for use by all stakeholders, from industry to regulators and healthcare providers.

01.27.12 | By Karl Uhlendorf

Yesterday, the New York Times' Well blog posted a commentary on DTC advertising. Although its underlying tone was one of skepticism, it did briefly touch on a couple of useful points.

01.26.12 | By Preet Bilinski

I think it's great that billionaire David Rubenstein has decided to donate half the $15 million needed to repair the damage to the Washington Monument from the earthquake last year. While I'm no David Rubenstein, I do appreciate the importance of giving back to your community, as do my colleagues. The staff at PhRMA have been participating in St. Matthew's Cathedral's annual Adopt-A-Family program for 6 years now. This year we were alarmed by the requests for basic items like dishes and bedding from our 'adopted families'.

01.25.12 | By Greg Lopes

In his recent commentary, Merill Goozner of the Fiscal Times looks at the affordability of cancer medicines. Goozner rightly points out that the biopharmaceutical industry is continuing to invest heavily in new treatments for this disease. However, access to treatment for chronic conditions such as cancer is a complex issue and the commentary fails to tell the entire story.

01.25.12 | By Kaelan Hollon

As I've mentioned before, mixed methodologies is an instant triple shot of espresso for me - I love the way humanities can influence the sciences, and the other way around.

01.25.12 | By Jenni Brewer

President Obama's State of the Union address and its focus on jobs comes at a time when America's biopharmaceutical research sector is developing nearly 3,000 medicines and bringing new treatment options to patients in need today -- all while supporting high-value jobs. Remarkable innovation is underway. Good American jobs are being created. But this progress can't continue if policies don't embrace the work (see PhRMA President John Castellani's statement on Tuesday night's SOTU).

Pages